Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Cash, Cash Equivalents, Marketable Securities : $840.44 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Cash, Cash Equivalents, Marketable Securities?

Ginkgo Bioworks Holdings's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($1,049.24 Mil) to Dec. 2023 ($944.07 Mil) but then stayed the same from Dec. 2023 ($944.07 Mil) to Mar. 2024 ($840.44 Mil).

Ginkgo Bioworks Holdings's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($1,550.00 Mil) to Dec. 2022 ($1,315.79 Mil) and declined from Dec. 2022 ($1,315.79 Mil) to Dec. 2023 ($944.07 Mil).

Ginkgo Bioworks Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Cash, Cash Equivalents, Marketable Securities Chart

Ginkgo Bioworks Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

380.80

1,550.00

1,315.79

944.07

Ginkgo Bioworks Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial											1,206.09	1,105.79	1,049.24	944.07	840.44

Ginkgo Bioworks Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Ginkgo Bioworks Holdings (NYSE:DNA.WS) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Ginkgo Bioworks Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA.WS) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

DNA:USA DNA:Mexico

Address

27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210

Website

https://www.ginkgobioworks.com

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.